TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03218592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc Pill
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pill
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Pill
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Study: NCT03340168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bisphenol-S
Description: Oral and dermal exposure in volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bisphenol-S
Description: Oral and dermal exposure in volunteers
Study: NCT00697775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine Formulation A
Description: Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine Formulation A
Description: Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine Formulation B
Description: 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
Study: NCT02366221

Intervention type: OTHER
Intervention: 60-minute visit to the outpatient clinic
Description: An interview, an injury-specific physical exam and/or a set of xrays.

Intervention type: OTHER
Intervention: Phone Interview
Description: If subject cannot return to office in Boston, researcher may conduct interview over the phone.
Study: NCT01621490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT04561128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819
Description: SHR-1819 will be subcutaneously administered with different dose levels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered with different dose levels
Study: NCT05484596

Intervention type: PROCEDURE
Intervention: Measuring VA Coupling
Description: Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
Study: NCT04159324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation
Description: the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
Study: NCT02053259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static Goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Goals
Study: NCT02115061

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Treatment: coil + cyanoacrylate
Description: This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment: cyanoacrylate
Description: This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
Study: NCT00365547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Topotecan 4 mg/m\^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
Study: NCT01741571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS guided FNA with and without suction
Description: Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS guided FNA with and without suction
Description: Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied.
Study: NCT01669200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglyceride Oil
Description: Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
Study: NCT02370069

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
Study: NCT02651649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
Study: NCT01630356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: in-person counseling
Description: The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demonstration of PM2.5 Pollution
Description: The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Counseling Calls
Description: Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed material
Description: The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed material
Description: The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency.
Study: NCT02929615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Study: NCT00911586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate
Study: NCT03693209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Description: VHS with a general anger trigger and 10 anger management strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Description: VHS with 10 specific anger triggers and 10 anger management strategies
Study: NCT03219671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg every 6 weeks
Study: NCT00168493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressants primarily selective serotonin reuptake inhibitors
Description: normal clinical dosages used according to clinical response as determined by a psychiatrist
Study: NCT00723125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
Study: NCT01036243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test formula 1
Description: hydrolyzed formula with probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: test formula 2
Description: acidified hydrolyzed formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: test formula 3
Description: hydrolyzed formula without probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: reference formula
Description: standard infant formula
Study: NCT05290012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
Study: NCT01095133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiloride
Description: dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
Study: NCT01621828

Intervention type: OTHER
Group type: OTHER
Intervention: video
Description: a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.

Intervention type: OTHER
Group type: OTHER
Intervention: leaflet
Description: a written leaflet, about the operating room experience and environment.
Study: NCT04436653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Replacement System
Description: To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
Study: NCT01240395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Description: MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
Study: NCT04555499

Intervention type: OTHER
Intervention: Standardized neurological examination
Study: NCT04049006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex treatment
Description: The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
Study: NCT03552042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterclockwise program
Description: A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
Study: NCT01489059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-982470 (recombinant interleukin-21)
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
Study: NCT03994484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablets
Description: Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Study: NCT04579614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers
Description: A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers
Description: A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers
Description: A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period.
Study: NCT03994757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MRBI
Description: The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.